



PRODUCT: **LORBRENA®**

COMPANY: Pfizer Inc.

THERAPEUTIC AREA & INDICATION:

For patients with anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC) in cases where previous ALK inhibitors have failed

ABOUT THE PRODUCT

LORBRENA is a third-generation ALK inhibitor specifically designed to inhibit the most common tumor mutations that drive resistance to current medications and to address metastases in the brain.

LORBRENA was first approved in 2018 – just four years from its discovery – for people with previously-treated ALK-positive NSCLC, and in 2021 received an expanded approval for those newly diagnosed with the disease.

During this time, LORBRENA has become an important treatment option for people with this rare type of lung cancer.